본문 바로가기
KERD
논문KCI 등재

난치 아토피피부염 전신 치료에 관한 전문가 의견서 업데이트

Update of systemic treatments in severe/recalcitrant atopic dermatitis: Consensus document of the KAAACI working group on atopic dermatitis

김현정|최응호|김미애|이미희|이소연|이동훈|이영수|김우경|최미라|민택기|염혜영|고영일|남동호|박 양|성명순|나정임|원종훈|난치성아토피피부염 연구팀
대한 소아알레르기 호흡기학회 (The Korean Academy Of Pediatric Allergy And Respiratory Disease)|2024.04|Allergy Asthma & Respiratory Disease (알레르기 천식 호흡기질환)|제12권 제2호|pp. 58-71|DOI https://doi.org/10.4168/aard.2024.12.2.58

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

Atopic dermatitisSevere atopic dermatitisRecalcitrant atopic dermatitisSystemic immunosuppressantsBiological agents
주제분류소아과학

초록

Atopic dermatitis (AD) is the most prevalent inflammatory skin condition, with approximately 80% of cases originating in childhood and some emerging in adulthood. In South Korea, the estimated prevalence of AD ranges between 10% and 20% in children and 1% and 3% in adults. Severe/recalcitrant AD manifests as a chronic, relapsing skin disorder, persisting with uncontrolled symptoms even after topical steroid treatment. Corticosteroids and systemic immunosuppression, conventionally the standard care for difficult-to-treat diseases, cause numerous undesirable side effects. When AD persists despite topical steroid application, systemic therapies like cyclosporine or systemic steroids become the second treatment strategy. The desire for targeted treatments, along with an enhanced understanding of AD’s pathophysiology, has spurred novel therapeutic development. Recent advances introduce novel systemic options, such as biological agents and small-molecule therapy, tailored to treat severe or recalcitrant AD. Notably, dupilumab, a monoclonal antibody inhibiting interleukin 4 and 13, marked a transformative breakthrough upon gaining approval from the U.S. Food and Drug Administration (FDA) in 2017, leading to a paradigm shift in the systemic treatment of AD. Furthermore, both dupilumab and Janus kinase inhibitors, including baricitinib, abrocitinib, and tofacitinib, now approved by the Korean FDA, have established their applicability in clinical practice. These innovative therapeutic agents have demonstrated favorable clinical outcomes, effectively addressing moderate to severe AD with fewer side reactions than those associated with previous systemic immunosuppressants. This review summarizes the latest advancements and evidence regarding systemic treatments for AD, including newly approved drugs in Korea.

Abstract

Atopic dermatitis (AD) is the most prevalent inflammatory skin condition, with approximately 80% of cases originating in childhood and some emerging in adulthood. In South Korea, the estimated prevalence of AD ranges between 10% and 20% in children and 1% and 3% in adults. Severe/recalcitrant AD manifests as a chronic, relapsing skin disorder, persisting with uncontrolled symptoms even after topical steroid treatment. Corticosteroids and systemic immunosuppression, conventionally the standard care for difficult-to-treat diseases, cause numerous undesirable side effects. When AD persists despite topical steroid application, systemic therapies like cyclosporine or systemic steroids become the second treatment strategy. The desire for targeted treatments, along with an enhanced understanding of AD’s pathophysiology, has spurred novel therapeutic development. Recent advances introduce novel systemic options, such as biological agents and small-molecule therapy, tailored to treat severe or recalcitrant AD. Notably, dupilumab, a monoclonal antibody inhibiting interleukin 4 and 13, marked a transformative breakthrough upon gaining approval from the U.S. Food and Drug Administration (FDA) in 2017, leading to a paradigm shift in the systemic treatment of AD. Furthermore, both dupilumab and Janus kinase inhibitors, including baricitinib, abrocitinib, and tofacitinib, now approved by the Korean FDA, have established their applicability in clinical practice. These innovative therapeutic agents have demonstrated favorable clinical outcomes, effectively addressing moderate to severe AD with fewer side reactions than those associated with previous systemic immunosuppressants. This review summarizes the latest advancements and evidence regarding systemic treatments for AD, including newly approved drugs in Korea.

참고문헌 (97)

  1. Bylund S, "Prevalence and incidence of atopic dermatitis: a systematic review", Acta Derm Venereol, 100, pp.adv00160~ (2020)
  2. Lee JY, "Time trends in the prevalence of atopic dermatitis in Korean children according to age", Allergy Asthma Immunol Res, 14, pp.123~130 (2022)
  3. Kim MJ, "Prevalence of atopic dermatitis among Korean adults visiting health service center of the Catholic Medical Center in Seoul Metropolitan Area, Korea", J Korean Med Sci, 25, pp.1828~1830 (2010)
  4. Wollenberg A, "Consensus-based European guidelines for treatment of atopic eczema(atopic dermatitis)in adults and children : part II", J Eur Acad Dermatol Venereol, 32, pp.850~878 (2018)
  5. Simpson EL, "When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council", J Am Acad Dermatol, 77, pp.623~633 (2017)
  6. Jun M, "Differences in genetic variations between treatable and recalcitrant atopic dermatitis in Korean", Allergy Asthma Immunol Res, 10, pp.244~252 (2018)
  7. Severity scoring of atopic dermatitis : the SCORAD index, "Consensus Report of the European Task Force on Atopic Dermatitis", Dermatology, 186, pp.23~31 (1993)
  8. Hanifin JM, "The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group", Exp Dermatol, 10, pp.11~18 (2001)
  9. Park JS, "KAAACI Work Group report on the treatment of severe", recalcitrant atopic dermatitis, 2010, pp.30, 255~270
  10. Leshem YA, "What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis : an interpretability study", Br J Dermatol, 172, pp.1353~1357 (2015)
  11. Chopra R, "Severity strata for Eczema Area and Severity Index(EASI), modified EASI, Scoring Atopic Dermatitis(SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis", Br J Dermatol, 177, pp.1316~1321 (2017)
  12. Kim JE, "2019 Consensus Korean diagnostic guidelines to define severity classification and treatment refractoriness for atopic dermatitis : objective and subjective assessment of severity", Ann Dermatol, 31, pp.654~661 (2019)
  13. Wollenberg A, "ETFAD", EADV eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children, 2020, pp.34, 2717~2744
  14. Lee JH, "Consensus update for systemic treatment of atopic dermatitis", Ann Dermatol, 33, pp.497~514 (2021)
  15. Saeki H, "English version of clinical practice guidelines for the management of atopic dermatitis 2021", J Dermatol, 49, pp.e315~e375 (2022)
  16. Wollenberg A, "European guideline(EuroGuiDerm)on atopic eczema : part I-systemic therapy", J Eur Acad Dermatol Venereol, 36, pp.1409~1431 (2022)
  17. Blauvelt A, "Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids(LIBERTY AD CHRONOS) : a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial", Lancet, 389, pp.2287~2303 (2017)
  18. Simpson EL, "Two phase 3 trials of dupilumab versus placebo in atopic dermatitis", N Engl J Med, 375, pp.2335~2348 (2016)
  19. de Bruin-Weller M, "Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable : a placebo-controlled, randomized phase III clinical trial(LIBERTY AD CAFÉ)", Br J Dermatol, 178, pp.1083~1101 (2018)
  20. Beck LA, "Dupilumab provides acceptable safety and sustained efficacy for up to 4 years in an open-label study of adults with moderate-to-severe atopic dermatitis", Am J Clin Dermatol, 23, pp.393~408 (2022)
  21. Halling AS, "Real-world evidence of dupilumab efficacy and risk of adverse events : a systematic review and meta-analysis", J Am Acad Dermatol, 84, pp.139~147 (2021)
  22. Jang DH, "A 52 weeks dupilumab treatment for moderate to severe atopic dermatitis in Korea : long-term efficacy and safety in real world", Sci Rep, 11, pp.23539~ (2021)
  23. Lee DH, "Real-world experience of long-term dupilumab treatment for atopic dermatitis in Korea", Ann Dermatol, 34, pp.157~160 (2022)
  24. Lee Y, "Real clinical practice data of monthly dupilumab therapy in adult patients with moderate-to-severe atopic dermatitis : clinical efficacy and predictive markers for a favorable clinical response", Allergy Asthma Immunol Res, 13, pp.733~745 (2021)
  25. Lee H, "One-year effectiveness and safety of dupilumab treatment for moderate-to-severe atopic dermatitis in Korean patients : a real-world retrospective analysis", Allergy Asthma Immunol Res, 14, pp.117~122 (2022)
  26. Yang N, "Dupilumab with concomitant Janus kinase inhibitor : a novel treatment strategy for atopic dermatitis with poor response to dupilumab", Br J Dermatol, 187, pp.828~830 (2022)
  27. Narla S, "Management of inadequate response and adverse effects to dupilumab in atopic dermatitis", J Am Acad Dermatol, 86, pp.628~636 (2022)
  28. Paller AS, "Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis : a randomized, double-blinded, placebo-controlled phase 3 trial", J Am Acad Dermatol, 83, pp.1282~1292 (2020)
  29. Simpson EL, "Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis : a phase 3 randomized clinical trial", JAMA Dermatol, 156, pp.44~56 (2020)
  30. Blauvelt A, "Long-term efficacy and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis : results through week 52 from a phase III open-label extension trial(LIBERTY AD PED-OLE)", Am J Clin Dermatol, 23, pp.365~383 (2022)
  31. Paller AS, "Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis : a randomised, double-blind, placebo-controlled, phase 3 trial", Lancet, 400, pp.908~919 (2022)
  32. Chovatiya R, "JAK inhibitors in the treatment of atopic dermatitis", J Allergy Clin Immunol, 148, pp.927~940 (2021)
  33. Nakashima C, "Innovation in the treatment of atopic dermatitis : emerging topical and oral Janus kinase inhibitors", Allergol Int, 71, pp.40~46 (2022)
  34. King B, "Extended safety analysis of baricitinib 2 mg in adult patients with atopic dermatitis : an integrated analysis from eight randomized clinical trials", Am J Clin Dermatol, 22, pp.395~405 (2021)
  35. Ferreira S, "Selective JAK1 inhibitors for the treatment of atopic dermatitis : focus on upadacitinib and abrocitinib", Am J Clin Dermatol, 21, pp.783~798 (2020)
  36. Chapman S, "Janus kinase inhibitors in dermatology: part I. A comprehensive review", J Am Acad Dermatol, 86, pp.406~413 (2022)
  37. Wollenberg A, "Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE-AD7 Phase 3 randomized trial", J Eur Acad Dermatol Venereol, 35, pp.1543~1552 (2021)
  38. Bieber T, "Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials", J Eur Acad Dermatol Venereol, 35, pp.476~485 (2021)
  39. Simpson EL, "Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis(JADE MONO-1) : a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial", Lancet, 396, pp.255~266 (2020)
  40. Silverberg JI, "Impact of oral abrocitinib monotherapy on patient-reported symptoms and quality of life in adolescents and adults with moderate-to-severe atopic dermatitis : a pooled analysis of patient-reported outcomes", Am J Clin Dermatol, 22, pp.541~554 (2021)
  41. Ständer S, "High threshold efficacy responses in moderate-to-severe atopic dermatitis are associated with additional quality of life benefits : pooled analyses of abrocitinib monotherapy studies in adults and adolescents", J Eur Acad Dermatol Venereol, 36, pp.1308~1317 (2022)
  42. Simpson EL, "Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the phase II and phase III clinical trial program", Am J Clin Dermatol, 22, pp.693~707 (2021)
  43. Guttman-Yassky E, "Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis(Measure Up 1 and Measure Up 2) : results from two replicate double-blind, randomised controlled phase 3 trials", Lancet, 397, pp.2151~2168 (2021)
  44. Blauvelt A, "Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis : a randomized clinical trial", JAMA Dermatol, 157, pp.1047~1055 (2021)
  45. Nakagawa H, "Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis : a phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study", J Am Acad Dermatol, 82, pp.823~831 (2020)
  46. Nakagawa H, "Delgocitinib ointment in pediatric patients with atopic dermatitis : a phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study", J Am Acad Dermatol, 85, pp.854~862 (2021)
  47. Papp K, "Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis : results from 2 phase 3, randomized, double-blind studies", J Am Acad Dermatol, 85, pp.863~872 (2021)
  48. Bissonnette R, "Topical tofacitinib for atopic dermatitis : a phase IIa randomized trial", Br J Dermatol, 175, pp.902~911 (2016)
  49. Oh MH, "TRPA1-dependent pruritus in IL-13-induced chronic atopic dermatitis", J Immunol, 191, pp.5371~5382 (2013)
  50. Shin JW, "Defective basement membrane in atopic dermatitis and possible role of IL-13", J Eur Acad Dermatol Venereol, 29, pp.2060~2062 (2015)
  51. Khattri S, "Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology", J Allergy Clin Immunol, 133, pp.1626~1634 (2014)
  52. Ungar B, "An integrated model of atopic dermatitis biomarkers highlights the systemic nature of the disease", J Invest Dermatol, 137, pp.603~613 (2017)
  53. Elias PM, ""Outside-to-inside"(and now back to"outside")pathogenic mechanisms in atopic dermatitis", J Invest Dermatol, 128, pp.1067~1070 (2008)
  54. Miron Y, "Mechanistic insights into the antipruritic effects of lebrikizumab, an anti-IL-13 mAb", J Allergy Clin Immunol, 150, pp.690~700 (2022)
  55. Oetjen LK, "Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch", Cell, 171, pp.217~228 (2017)
  56. Bieber T, "Interleukin-13 : targeting an underestimated cytokine in atopic dermatitis", Allergy, 75, pp.54~62 (2020)
  57. Simpson EL, "Efficacy and safety of lebrikizumab(an anti-IL-13 monoclonal antibody)in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids : a randomized, placebo-controlled phase II trial(TREBLE)", J Am Acad Dermatol, 78, pp.863~871 (2018)
  58. Guttman-Yassky E, "Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis : a phase 2b randomized clinical trial", JAMA Dermatol, 156, pp.411~420 (2020)
  59. "Safety and efficacy of lebrikizumab (LY3650150) in combination with topical corticosteroid in moderate-to-severe atopic dermatitis. (ADhere)" (2022)[URL]
  60. "Evaluation of the efficacy and safety of lebrikizumab (LY3650150) in moderate to severe atopic dermatitis" (2022)[URL]
  61. Popovic B, "Structural characterisation reveals mechanism of IL-13-neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13Rα1 and IL-13Rα2", J Mol Biol, 429, pp.208~219 (2017)
  62. "Adtralza 150 mg solution for injection in pre-filled syringe" (2021)[URL]
  63. Wollenberg A, "Tralokinumab for moderate-to-severe atopic dermatitis : results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials(ECZTRA 1 and ECZTRA 2)", Br J Dermatol, 184, pp.437~449 (2021)
  64. Silverberg JI, "Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis : results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial", Br J Dermatol, 184, pp.450~463 (2021)
  65. Gutermuth J, "Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A : a placebo-controlled, randomized, phase III clinical trial(ECZTRA 7)", Br J Dermatol, 186, pp.440~452 (2022)
  66. Bieber T, "Atopic dermatitis : an expanding therapeutic pipeline for a complex disease", Nat Rev Drug Discov, 21, pp.21~40 (2022)
  67. FitzGerald JM, "Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma(CALIMA) : a randomised, double-blind, placebo-controlled phase 3 trial", Lancet, 388, pp.2128~2141 (2016)
  68. Pavord ID, "Mepolizumab for severe eosinophilic asthma(DREAM) : a multicentre, double-blind, placebo-controlled trial", Lancet, 380, pp.651~659 (2012)
  69. Prazma CM, "Response to mepolizumab treatment in patients with severe eosinophilic asthma and atopic phenotypes", J Asthma Allergy, 14, pp.675~683 (2021)
  70. "Efficacy and safety study of the use of benralizumab for patients with moderate to severe atopic dermatitis" (2023)[URL]
  71. Ruzicka T, "Anti-interleukin-31 receptor a antibody for atopic dermatitis", N Engl J Med, 376, pp.826~835 (2017)
  72. Silverberg JI, "Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus", J Allergy Clin Immunol, 145, pp.173~182 (2020)
  73. Kabashima K, "Trial of nemolizumab and topical agents for atopic dermatitis with pruritus", N Engl J Med, 383, pp.141~150 (2020)
  74. Kabashima K, "Nemolizumab plus topical agents in patients with atopic dermatitis(AD)and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks : results from two phase III, long-term studies", Br J Dermatol, 186, pp.642~651 (2022)
  75. Czarnowicki T, "Atopic dermatitis endotypes and implications for targeted therapeutics", J Allergy Clin Immunol, 143, pp.1~11 (2019)
  76. Ungar B, "Phase 2 randomized, double-blind study of IL-17 targeting with secukinumab in atopic dermatitis", J Allergy Clin Immunol, 147, pp.394~397 (2021)
  77. Guttman-Yassky E, "Efficacy and safety of fezakinumab(an IL-22 monoclonal antibody)in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments : a randomized, double-blind, phase 2a trial", J Am Acad Dermatol, 78, pp.872~881 (2018)
  78. Brunner PM, "Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab", J Allergy Clin Immunol, 143, pp.142~154 (2019)
  79. Guttman-Yassky E, "GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis", J Allergy Clin Immunol, 144, pp.482~493 (2019)
  80. Yang N, "Novel targeted biological agents for the treatment of atopic dermatitis", BioDrugs, 35, pp.401~415 (2021)
  81. Otobe S, "Increased interleukin-36gamma expression in skin and sera of patients with atopic dermatitis and mycosis fungoides", Sezary syndrome, 2018, pp.45, 468~471
  82. Wollenberg A, "Targeting immunoglobulin E in atopic dermatitis : a review of the existing evidence", World Allergy Organ J, 14, pp.100519~ (2021)
  83. Chan S, "Treatment effect of Omalizumab on severe pediatric atopic dermatitis : the ADAPT randomizedclinical trial", JAMA Pediatr, 174, pp.29~37 (2020)
  84. Werfel T, "Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites : a multi-centre, randomized, dose-response study", Allergy, 61, pp.202~205 (2006)
  85. Novak N, "Efficacy and safety of subcutaneous allergen-specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis", J Allergy Clin Immunol, 130, pp.925~931 (2012)
  86. Pajno GB, "Sublingual immunotherapy in mite-sensitized children with atopic dermatitis : a randomized, double-blind, placebo-controlled study", J Allergy Clin Immunol, 120, pp.164~170 (2007)
  87. Yu N, "Sublingual immunotherapy in mite-sensitized patients with atopic dermatitis : a randomized controlled study", Postepy Dermatol Alergol, 38, pp.69~74 (2021)
  88. Langer SS, "Efficacy of house dust mite sublingual immunotherapy in patients with atopic dermatitis : a randomized, double-blind, placebo-controlled trial", J Allergy Clin Immunol Pract, 10, pp.539~549 (2022)
  89. Bae JM, "Efficacy of allergen-specific immunotherapy for atopic dermatitis : a systematic review and meta-analysis of randomized controlled trials", J Allergy Clin Immunol, 132, pp.110~117 (2013)
  90. Yepes-Nuñez JJ, "Allergen immunotherapy for atopic dermatitis : systematic review and meta-analysis of benefits and harms", J Allergy Clin Immunol, 151, pp.147~158 (2023)
  91. Novak N, "Allergen specific immunotherapy for atopic dermatitis", Curr Opin Allergy Clin Immunol, 7, pp.542~546 (2007)
  92. Lee J, "Retrospective analysis on the effects of house dust mite specific immunotherapy for more than 3 years in atopic dermatitis", Yonsei Med J, 57, pp.393~398 (2016)
  93. Nahm DH, "Clinical efficacy of subcutaneous allergen immunotherapy in patients with atopic dermatitis", Yonsei Med J, 57, pp.1420~1426 (2016)
  94. Dogra S, "Phototherapy for atopic dermatitis", Indian J Dermatol Venereol Leprol, 81, pp.10~15 (2015)
  95. Musters AH, "Phototherapy for atopic eczema", Cochrane Database Syst Rev, 10, pp.CD013870~ (2021)
  96. Tintle S, "Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response", J Allergy Clin Immunol, 128, pp.583~593 (2011)
  97. Choi JY, "Narrowband ultraviolet B phototherapy is associated with a reduction in topical corticosteroid and clinical improvement in atopic dermatitis : a historical inception cohort study", Clin Exp Dermatol, 46, pp.1067~1074 (2021)

관련 논문AI추천

Consensus-Based Guidelines for the Treatment of Atopic Dermatitis in Korea (Part II): Biologics and JAK inhibitors고주연, 고현창, 나찬호, 서영준, 손상욱, 신민경, 안지영, 유박린, 이동훈, 이상은, 이설희, 장용현, 전지현, 한태영, Bae Youin, Choi Sun Young, Cho Sang Hyun, Han Ju Hee, Kim Hye One, Lee Ji Hyun, Lee Yang Won, Woo Yu Ri대한피부과학회 · Annals of Dermatology2025 · 제37권 제4호소아 아토피피부염의 최신 치료김정희, 전유훈대한 소아알레르기 호흡기학회 · Allergy Asthma & Respiratory Disease2021 · 제9권 제2호Consensus Update for Systemic Treatment of Atopic Dermatitis김정은, 김혜원, 나찬호, 노주영, 박영립, 박창욱, 배정민, 변지연, 서영준, 손상욱, 신민경, 안지영, 유박린, 이양원, 이지현, 장용현, 최응호, 한태영, 홍승필, Park Gyeong-Hun대한피부과학회 · Annals of Dermatology2021 · 제33권 제6호Consensus-Based Guidelines for the Treatment of Atopic Dermatitis in Korea (Part I): Basic Therapy, Topical Therapy, and Conventional Systemic Therapy고주연, 고현창, 나찬호, 서영준, 신민경, 안지영, 유박린, 이동훈, 이상은, 이설희, 장용현, 전지현, 한태영, Bae Youin, Choi Sun Young, Cho Sang Hyun, Han Ju Hee, Kim Hye One, Lee Ji Hyun, Lee Yang Won, Son Sang Wook, Woo Yu Ri대한피부과학회 · Annals of Dermatology2025 · 제37권 제4호난치성 아토피피부염 Work Group 보고서: 난치성 아토피피부염의 치료에 관한 전문가 의견서박양, 김규한, 김범준, 김우경, 김정은, 김현희, 남동호, 박준수, 염혜영, 오재원, 이소연, 이애영, 홍수종, 대한천식알레르기학회대한천식알레르기학회 · 천식 및 알레르기2010 · 제30권 제4호청소년과 성인 아토피피부염 환자에서 dupilumab의 임상효과와 순응도: 한국의 단일 알레르기 클리닉의 실제 진료 상황에서의 관찰 결과 분석김명은, 남동호, 이영수대한 소아알레르기 호흡기학회 · Allergy Asthma & Respiratory Disease2023 · 제11권 제2호

이 간행물의 다른 논문 (6건)

국내 소아 생선 알레르기 진단과 관리의 현재정민영pp. 45-47후두 기능이상: 정의와 진단법강유리, 유영상, 송우정, 이지향, 오지윤pp. 48-57한국 소아에서 흰살생선 알레르기: 단일기관 후향적 연구박그믐, 프레브산, 염상화, 이수영, 정경욱pp. 72-77소아청소년의 구강알레르기증후군을 중심으로 한 면역글로불린 E 매개 음식알레르기에 대한 고찰한만용, 김주희, 신지원, 지혜미, 신윤호, 하은교pp. 78-84부산지역 접촉성피부염 의심 환자에서 첩포검사 결과 분석오지현, 김광석, 김희규, 박찬선, 최길순pp. 85-92
원문 보기